KRAS and neoplasm: Furthermore, a patient with a BRAF V600E-mutant, wt KRAS colorectal cancer, with a history of early progression to cetuximab-based therapy, was found to have a KRAS G12D mutation (24.39%) in cfDNA instead, which was not previously detected in the tumor tissue.